Form 4: Biodesix CEO Acquires Convertible Preferred Stock

Scott Hutton, President & CEO of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock on April 5, 2024, which is subject to stockholder approval for conversion into common stock.

Summary

• On April 5, 2024, Scott Hutton, the President & CEO of Biodesix Inc., acquired 653 shares of Series A Non-Voting Convertible Preferred Stock.
• These shares were issued under securities purchase agreements and are contingent upon stockholder approval at the 2024 annual meeting for conversion into common stock.
• Each share of preferred stock will convert into 40 shares of common stock upon approval, with a limitation preventing Hutton from owning more than 19.9% of the total outstanding common stock after conversion.
• The preferred stock has no expiration date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The CEO's investment in preferred stock suggests confidence in the company. However, the conversion is subject to stockholder approval and ownership limitations.

Positives

• The acquisition of preferred stock by the CEO demonstrates his investment and confidence in the company's future.
• The conversion feature provides a potential upside for the CEO if the company's common stock performs well.

Risks

• Stockholder approval for the conversion of preferred stock into common stock is not guaranteed.
• The 19.9% ownership limitation may restrict the CEO's ability to fully convert the preferred stock.

Future Outlook

The conversion of the preferred stock is contingent upon stockholder approval at the 2024 annual meeting.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's confidence in the company's prospects. This transaction indicates the CEO's belief in Biodesix's future.

Stakeholder Impact

• Shareholders will vote on the conversion proposal, which could impact the outstanding share count.
• Employees may be affected by the potential changes in company strategy and performance.

Next Steps

• Biodesix will seek stockholder approval for the conversion of the preferred stock at the 2024 annual meeting.

Key Dates